Share-based Payment Arrangement, Expense of Acumen Pharmaceuticals, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Acumen Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • Acumen Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,461,000, a 5.3% increase year-over-year.
  • Acumen Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $9,776,000, a 9.5% increase year-over-year.
  • Acumen Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $9,635,000, a 57% increase from 2023.
  • Acumen Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6,145,000, a 101% increase from 2022.
  • Acumen Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3,061,000, a 232% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Acumen Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $9,776,000 $2,461,000 +$123,000 +5.3% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $9,653,000 $2,498,000 +$28,000 +1.1% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $9,625,000 $2,474,000 -$10,000 -0.4% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $9,635,000 $2,343,000 +$709,000 +43% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $8,926,000 $2,338,000 +$738,000 +46% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $8,188,000 $2,470,000 +$949,000 +62% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $7,239,000 $2,484,000 +$1,094,000 +79% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $6,145,000 $1,634,000 +$746,000 +84% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $5,399,000 $1,600,000 +$760,000 +90% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $4,639,000 $1,521,000 +$806,000 +113% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $3,833,000 $1,390,000 +$772,000 +125% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $3,061,000 $888,000 +$523,000 +143% 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
Q3 2022 $2,538,000 $840,000 +$536,000 +176% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $2,002,000 $715,000 +$588,000 +463% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $1,414,000 $618,000 +$492,000 +390% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $922,000 $365,000 01 Oct 2021 31 Dec 2021 10-K 27 Mar 2023 2022 FY
Q3 2021 $304,000 +$265,000 +679% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $127,000 +$89,000 +234% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $126,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 $39,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $38,000 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2

Acumen Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $9,635,000 +$3,490,000 +57% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $6,145,000 +$3,084,000 +101% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $3,061,000 +$2,139,000 +232% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
2021 $922,000 +$768,000 +499% 01 Jan 2021 31 Dec 2021 10-K 27 Mar 2023 2022 FY
2020 $154,000 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.